Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKinsey
Mallinckrodt
Teva
Baxter
McKesson
Moodys
Cerilliant
Argus Health

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,653,286

« Back to Dashboard

Summary for Patent: 6,653,286
Title: Gonadotropin releasing hormone antagonist
Abstract:The present invention relates to a method to prevent a premature LH surge. The method employs the administration of the gonadotropin releasing hormone antagonist ganirelix in an amount between 0.125-1 mg in combination with exogenous FSH. The method can be used in the treatment of women undergoing controlled ovarian superovulation.
Inventor(s): Mannaerts; Bernadette Maria Julia Louise (Acacialaan, NL), Coelingh Bennink; Herman Jan Tijmen (Melvill van Carnebeelaan, NL), Orlemans; Everardus Otto Maria (Wolvespoor, NL)
Assignee: Akzo Nobel NV (Arnhem, NL)
Application Number:09/446,324
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,653,286
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 6,653,286

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Organon Usa Inc GANIRELIX ACETATE ganirelix acetate INJECTABLE;INJECTION 021057-001 Jul 29, 1999 RX Yes Yes ➤ Sign Up ➤ Sign Up INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,653,286

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
97201885Jun 20, 1997
PCT Information
PCT FiledJune 16, 1998PCT Application Number:PCT/EP98/03713
PCT Publication Date:December 30, 1998PCT Publication Number: WO98/58657

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Dow
Deloitte
Cerilliant
Citi
Moodys
Mallinckrodt
Queensland Health
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.